Arthrosi Therapeutics
Clinical trials sponsored by Arthrosi Therapeutics, explained in plain language.
-
New hope for gout sufferers who failed last resort treatment
Disease control OngoingThis study tests a new oral medication, AR882, taken with a standard gout drug (XOI) in 15 adults with uncontrolled gout who could not tolerate or stopped responding to uricase infusions. The goal is to lower uric acid levels below 6 mg/dL and shrink painful uric acid crystal dep…
Phase: PHASE2 • Sponsor: Arthrosi Therapeutics • Aim: Disease control
Last updated May 26, 2026 08:19 UTC
-
New gout drug shows promise in major trial
Disease control OngoingThis study tests a new medicine called AR882 in 750 adults with gout. The goal is to see if it can lower uric acid levels and reduce painful gout flares over 12 months. Participants receive either AR882 or a placebo. This is a phase 3 trial, meaning it is one of the final steps b…
Phase: PHASE3 • Sponsor: Arthrosi Therapeutics • Aim: Disease control
Last updated May 20, 2026 12:04 UTC